Whole genome sequencing (WGS) of matched samples of IDH-mutant low-grade glioma prior to and after treatment with safusidenib.
Library preparation for whole genome/whole transcriptome sequencing was conducted using genomic DNA and RNA from pre- and post-safusidenib tumor samples, along with matched germline DNA. An input of 200 ng was used with the TruSeq DNA nano kit (Illumina), or the NEBNext rRNA depletion kit and Ultra II directional RNA library kit for Illumina (New England Biolabs), which was conducted and sequenced to a depth of 40x for normal and 80x for tumour on an Illumina NovaSeq 6000 at the University of Melbourne Centre for Cancer Research (Melbourne, Australia). Briefly, whole genome transcriptome analysis was performed using the University of Melbourne Centre for Cancer Research analysis pipeline, as described previously. Detected genomic variants were analyzed and classified by the level of evidence based on clinical significance according to AMP/ASCO/CAP guidelines.